Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 56.13
BIOL's Cash-to-Debt is ranked higher than
74% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. BIOL: 56.13 )
Ranked among companies with meaningful Cash-to-Debt only.
BIOL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24  Med: 4 Max: No Debt
Current: 56.13
Equity-to-Asset 0.53
BIOL's Equity-to-Asset is ranked lower than
59% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. BIOL: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
BIOL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35  Med: 0.45 Max: 0.83
Current: 0.53
-0.35
0.83
Interest Coverage N/A
BIOL's Interest Coverage is ranked higher than
76% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. BIOL: N/A )
Ranked among companies with meaningful Interest Coverage only.
BIOL' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.5 Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 4
Altman Z-Score: -2.70
Beneish M-Score: -3.04
WACC vs ROIC
9.39%
-107.89%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -28.88
BIOL's Operating Margin % is ranked lower than
78% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. BIOL: -28.88 )
Ranked among companies with meaningful Operating Margin % only.
BIOL' s Operating Margin % Range Over the Past 10 Years
Min: -43.83  Med: -16.54 Max: -4.41
Current: -28.88
-43.83
-4.41
Net Margin % -29.67
BIOL's Net Margin % is ranked lower than
77% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. BIOL: -29.67 )
Ranked among companies with meaningful Net Margin % only.
BIOL' s Net Margin % Range Over the Past 10 Years
Min: -45.84  Med: -17.24 Max: -5.33
Current: -29.67
-45.84
-5.33
ROE % -77.27
BIOL's ROE % is ranked lower than
87% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. BIOL: -77.27 )
Ranked among companies with meaningful ROE % only.
BIOL' s ROE % Range Over the Past 10 Years
Min: -492.46  Med: -72.64 Max: -25.09
Current: -77.27
-492.46
-25.09
ROA % -37.82
BIOL's ROA % is ranked lower than
82% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. BIOL: -37.82 )
Ranked among companies with meaningful ROA % only.
BIOL' s ROA % Range Over the Past 10 Years
Min: -59.62  Med: -29.63 Max: -9.89
Current: -37.82
-59.62
-9.89
ROC (Joel Greenblatt) % -119.67
BIOL's ROC (Joel Greenblatt) % is ranked lower than
78% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. BIOL: -119.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIOL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -445.37  Med: -127.85 Max: -36.01
Current: -119.67
-445.37
-36.01
3-Year Revenue Growth Rate -20.80
BIOL's 3-Year Revenue Growth Rate is ranked lower than
86% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. BIOL: -20.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIOL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -56.4  Med: 1.05 Max: 104.2
Current: -20.8
-56.4
104.2
3-Year EBITDA Growth Rate -10.30
BIOL's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. BIOL: -10.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIOL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.4  Med: -8.55 Max: 92.1
Current: -10.3
-50.4
92.1
3-Year EPS without NRI Growth Rate -6.10
BIOL's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. BIOL: -6.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIOL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.3  Med: -7.05 Max: 142.2
Current: -6.1
-53.3
142.2
GuruFocus has detected 2 Warning Signs with Biolase Inc $BIOL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIOL's 10-Y Financials

Financials (Next Earnings Date: 2017-06-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BIOL Guru Trades in Q1 2016

Mario Gabelli 91,455 sh (unchged)
» More
Q2 2016

BIOL Guru Trades in Q2 2016

Charles Brandes 23,093 sh (New)
Mario Gabelli 91,455 sh (unchged)
» More
Q3 2016

BIOL Guru Trades in Q3 2016

Jim Simons 35,652 sh (New)
Mario Gabelli 91,455 sh (unchged)
Charles Brandes Sold Out
» More
Q4 2016

BIOL Guru Trades in Q4 2016

Jim Simons 59,052 sh (+65.63%)
Mario Gabelli 91,000 sh (-0.50%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339114    SIC: 3843
Compare:NAS:EKSO, NAS:HBIO, AMEX:BVX, NAS:LAKE, NAS:LENS, AMEX:INFU, NAS:VLRX, OTCPK:TSNLF, NAS:IVTY, AMEX:MLSS, NAS:CASM, AMEX:RVP, AMEX:ISR, OTCPK:UNISQ, OTCPK:TDMMF, AMEX:TRXC, AMEX:DXR, NAS:BLFS, NAS:ATEC, OTCBB:NEPH » details
Traded in other countries:BTH.Germany,
Headquarter Location:USA
Biolase Inc is a medical device company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment.

Biolase Inc was originally formed as Societe Endo Technic, SA ("SET") in 1984 in Marseilles, France. In 1987, SET merged into Pamplona Capital Corp., a public holding company incorporated in Delaware. In 1994, it changed its name to BIOLASE Technology, Inc. and to BIOLASE, Inc. ("BIOLASE") in 2012. The Company is a biomedical company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional ("3-D") printers; products that are focused on technologies that advance the practice of dentistry and medicine. Its proprietary dental laser systems allows dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a dental procedures, including cosmetic, restorative, and complex surgical applications. Its systems are designed to provide performance for many types of dental procedures with less pain and faster recovery times than are generally achieved with drills, scalpels, and other conventional instruments. The Company has clearance from the U.S. Food and Drug Administration (the "FDA") to sell its laser systems in the United States and also have the necessary registration to sell its laser systems in Canada, the European Union, and various other international markets. Its licensed dental imaging equipment and other related products are designed to improve diagnoses, applications, and procedures in dentistry and medicine. It offers two categories of laser system products: WaterLase systems and Diode systems. Its WaterLase system, uses a patented combination of water and laser energy to perform most procedures currently performed using dental drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. It currently has approximately 180 issued and 120 pending U.S. and international patents, the majority of which are related to WaterLase technology and dental and medical lasers.

Ratios

vs
industry
vs
history
PB Ratio 3.89
BIOL's PB Ratio is ranked lower than
59% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. BIOL: 3.89 )
Ranked among companies with meaningful PB Ratio only.
BIOL' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 6.11 Max: 43.33
Current: 3.89
0.87
43.33
PS Ratio 1.45
BIOL's PS Ratio is ranked higher than
73% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. BIOL: 1.45 )
Ranked among companies with meaningful PS Ratio only.
BIOL' s PS Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.5 Max: 5.36
Current: 1.45
0.13
5.36
EV-to-EBIT -5.34
BIOL's EV-to-EBIT is ranked lower than
99.99% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. BIOL: -5.34 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOL' s EV-to-EBIT Range Over the Past 10 Years
Min: -83.2  Med: -8.4 Max: -0.3
Current: -5.34
-83.2
-0.3
EV-to-EBITDA -5.73
BIOL's EV-to-EBITDA is ranked lower than
99.99% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. BIOL: -5.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -154.3  Med: -9.1 Max: 10951
Current: -5.73
-154.3
10951
Current Ratio 1.89
BIOL's Current Ratio is ranked lower than
66% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. BIOL: 1.89 )
Ranked among companies with meaningful Current Ratio only.
BIOL' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.54 Max: 5.5
Current: 1.89
0.63
5.5
Quick Ratio 1.14
BIOL's Quick Ratio is ranked lower than
71% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. BIOL: 1.14 )
Ranked among companies with meaningful Quick Ratio only.
BIOL' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.14 Max: 5
Current: 1.14
0.35
5
Days Inventory 147.06
BIOL's Days Inventory is ranked lower than
63% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. BIOL: 147.06 )
Ranked among companies with meaningful Days Inventory only.
BIOL' s Days Inventory Range Over the Past 10 Years
Min: 86.85  Med: 136.7 Max: 158.88
Current: 147.06
86.85
158.88
Days Sales Outstanding 68.93
BIOL's Days Sales Outstanding is ranked lower than
63% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. BIOL: 68.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.23  Med: 66.93 Max: 74.33
Current: 68.93
21.23
74.33
Days Payable 105.73
BIOL's Days Payable is ranked higher than
80% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. BIOL: 105.73 )
Ranked among companies with meaningful Days Payable only.
BIOL' s Days Payable Range Over the Past 10 Years
Min: 66.88  Med: 87.64 Max: 105.73
Current: 105.73
66.88
105.73

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.10
BIOL's 3-Year Average Share Buyback Ratio is ranked lower than
87% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. BIOL: -24.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIOL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.9  Med: -6.65 Max: -0.5
Current: -24.1
-45.9
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 6.05
BIOL's Price-to-Net-Current-Asset-Value is ranked higher than
55% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. BIOL: 6.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BIOL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.8  Med: 16.08 Max: 196
Current: 6.05
2.8
196
Price-to-Tangible-Book 4.54
BIOL's Price-to-Tangible-Book is ranked higher than
50% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. BIOL: 4.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIOL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.23  Med: 11.25 Max: 75
Current: 4.54
2.23
75
Price-to-Median-PS-Value 0.96
BIOL's Price-to-Median-PS-Value is ranked higher than
64% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. BIOL: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIOL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 2.26 Max: 46.13
Current: 0.96
0.37
46.13
Earnings Yield (Greenblatt) % -18.76
BIOL's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. BIOL: -18.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIOL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -121.54  Med: 1.8 Max: 2.3
Current: -18.76
-121.54
2.3

More Statistics

Revenue (TTM) (Mil) $51.81
EPS (TTM) $ -0.28
Beta1.20
Short Percentage of Float7.85%
52-Week Range $0.80 - 1.98
Shares Outstanding (Mil)67.66
» More Articles for BIOL

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: Biolase, AES Corporation, FireEye Nov 16 2015 
Viral Cross-Contamination Risks at the Dentist Office Jan 14 2015 
UPDATE - Ebola and Other Viral Cross-Contamination Risks at the Dentist Office Jan 14 2015 

More From Other Websites
BIOLASE to Raise $10.5 Million from Institutional and Individual Investors in a Private Placement Apr 13 2017
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Mar 28 2017
ETFs with exposure to BIOLASE, Inc. : March 27, 2017 Mar 27 2017
BIOLASE, Inc. :BIOL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
BIOLASE to Showcase Two New Game-Changing Products at International Dental Show in Cologne Mar 20 2017
BIOLASE, Inc. :BIOL-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
BIOLASE Names James D. Surek Vice President Sales, Americas Mar 13 2017
BIOLASE to Present at the 29th Annual ROTH Conference Mar 09 2017
Biolase reports 4Q loss Mar 08 2017
BIOLASE Reports 2016 Full Year and Fourth Quarter Results Mar 08 2017
BIOLASE Names Mark J. Nelson Chief Financial Officer Mar 01 2017
BIOLASE® to Host 2016 Fourth Quarter Financial Results Conference Call on March 8 Mar 01 2017
BIOLASE to Host ‘Lasers for Every Dentist’ Launch Celebration at Chicago Midwinter Dental... Feb 21 2017
BIOLASE Announces the FDA Clearance and Worldwide Launch of New Waterlase Express™ All-Tissue... Feb 10 2017
BIOLASE Announces the FDA Clearance and Worldwide Launch of Its New Epic Pro™ Diode Laser System Jan 23 2017
BIOLASE Announces Management Change Jan 09 2017
ETFs with exposure to BIOLASE, Inc. : January 3, 2017 Jan 03 2017
BIOLASE Inc (BIOL): How It Stacks Up Against Its Peers Dec 13 2016
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BIOLASE, Inc. for Potential... Nov 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)